
Human Recombinant Apelin Receptor Stable Cell Line**Cat. No. M00245****Version 07272020**

I. Introduction	1
II. Background	1
III. Representative Data	2
IV. Thawing and Subculturing	2
V. References	3
VI. Limited Use License Agreement.....	4

I. INTRODUCTION

Catalog Number: M00245

Cell Line Name: CHO-K1/AGTRL1/G α 15

Gene Synonyms: APJ; APLNR; FLJ90771; MGC45246; AGTRL1; HG11; APJR; FLJ96609

Expressed Gene: Genbank Accession Number NM_005161; no expressed tags

Host Cell: CHO-K1/G α 15Quantity: 2 vial (>1 \times 10⁶ per vial) frozen cells

Stability: More than 16 passages

Application: Functional assay for AGTRL1 receptor (calcium flux assay, cAMP assay)

Freeze Medium: 45% culture medium, 45% FBS (Cat. #10099-141, Gibco), 10% DMSO (Cat. #D2650, Sigma)

Complete Growth Medium: Ham's F-12 K (Kaighn's) (Cat. #21127, Life Technologies), 10% FBS

Culture Medium: Ham's F-12 K (Kaighn's), 10% FBS, 100 μ g/ml Hygromycin B (Cat. #10687010, Invitrogen), 400 μ g/ml G418 (Cat. #10131-035, Gibco)

Mycoplasma Status: Negative*

Storage: Liquid nitrogen immediately upon receipt

II. BACKGROUND

The apelin receptor AGTRL1 is G_i/G_o-coupled GPCRs expressed in the heart, coronary artery, aorta, internal mammary artery, pulmonary artery and saphenous vein, it also expressed in lung, kidney and adrenal gland. In AGTRL1 receptor knockout mice baseline blood pressure is not changed compared to wild-type animals. Vasoconstrictor responses to angiotensin II however are significantly more pronounced in the knockout animals.

* The mycoplasma test was performed with MycoAlert™ PLUS Mycoplasma Detection Kit of Lonza.

III. REPRESENTATIVE DATA

Concentration-dependent stimulation of intracellular calcium mobilization by Apelin-13 in CHO-K1/AGTRL1/Gα15 cells




Figure 1. Apelin-13-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/AGTRL1/Gα15 cells. The cells were loaded with Calcium-4 prior to being stimulated with an AGTRL1 receptor agonist, Apelin-13. The intracellular calcium change was measured by FLIPR. The relative fluorescent units (RFU) were normalized and plotted against the log of the cumulative doses (10-fold dilution) of Apelin-13 (Mean ± SD, n = 2). The EC₅₀ of Apelin-13 on this cells was 0.19 μM.

Notes:

- EC₅₀ value is calculated with four parameter logistic equation:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) * \text{HillSlope}))}$$
 X is the logarithm of concentration. Y is the response
 Y is RFU and starts at Bottom and goes to Top with a sigmoid shape.

IV. THAWING AND SUBCULTURING

Thawing Protocol

- Remove the vial from liquid nitrogen tank and thaw cells quickly in a 37°C water-bath.
- Just before the cells are completely thawed, decontaminate the outside of the vial with 70% ethanol and transfer the cells to a 15 ml centrifuge tube containing 9 ml of complete growth medium.
- Pellet cells by centrifugation at 200 x g force for 5 min, and remove the medium.
- Resuspend the cells in complete growth medium.
- Transfer the cell suspension to a 10 cm dish with 10 ml of complete growth medium.
- Grow the cells in incubator with 37°C, 5 %CO₂.

7. Add antibiotic in the following day.

Sub-culturing Protocol

1. Remove the culture medium from cells.
2. Wash cells with PBS (pH=7.4) to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 ml of 0.05% (w/v) Trypsin- EDTA (GIBCO, Cat No. 25300) solution into 10 cm dish and observe the cells under an inverted microscope until cell layer is dispersed (usually within 3 to 5 minutes).

Note: To avoid cells clumping, do not agitate the cells by hitting or shaking the dish while waiting for the cells detach. If cells are difficult to detach, please place the dish in 37°C incubator for ~2 min.

4. Add 6.0 to 8.0 ml of complete growth medium into dish and aspirate cells by gently pipetting.
5. Centrifuge the cells at 200 x g force for 5min, and remove the medium.
6. Resuspend the cells in culture medium and add the cells suspension to new culture dish.
7. Grow the cells in incubator with 37°C, 5 %CO₂.

Subcultivation Ratio: 1:3 to 1:8

Medium Renewal: Every 2 to 3 days

V. REFERENCES

1. Hosoya M, *et al.* (2000) Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. *J Biol Chem.* 275(28):21061-7.
2. Masri B, *et al.* (2002) Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. *Biochem Biophys Res Commun.* 290(1):539-45
3. Kawamata Y, *et al.* (2001) Molecular properties of apelin: tissue distribution and receptor binding. *Biochim Biophys Acta.* 1538(2-3):162-71
4. Ishida J, *et al.* (2004) Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. *J Biol Chem.* 279(25):26274-9. Epub 2004 Apr 15

GenScript USA Inc,

860 Centennial Ave.

Piscataway, NJ 08854

Toll-Free: 1-877-436-7274

Tel: 1-732-885-9188, Fax: 1-732-210-0262

Email: product@genscript.com

Web: <http://www.genscript.com>

For Research Use Only.

Limited Use License Agreement

This is a legal agreement between you (Licensee) and GenScript USA Inc. governing use of GenScript's stable cell line products and protocols provided to licensee. By purchasing and using the stable cell line, the buyer agrees to comply with the following terms and conditions of this label license and recognizes and agrees to such restrictions:

- 1) The products are not transferable and will be used at the site where they were purchased. Transfer to another site owned by buyer will be permitted only upon written request by buyer followed by subsequent written approval by GenScript.
- 2) The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party.
- 3) The products sold by GenScript are for laboratory and animal research purposes only. The products are not to be used on humans, for consumption, or for any unlawful uses.

GenScript USA Inc. will not assert against the buyer a claim of infringement of patents owned or controlled by GenScript USA Inc. and claiming this product based upon the manufacture, use or sale of a clinical diagnostic, therapeutic and vaccine, or prophylactic product developed in research by the buyer in which this product or its components has been employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on the use of this product for other purposes, contact Marketing Department, GenScript USA Inc., 860 Centennial Ave. Piscataway, NJ 08854, U.S.A. Phone: 1-732-885-9188. Fax: 1-732-210-0262. Email: marketing@genscript.com.